Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(62.5%)
Phase 3
3(37.5%)
8Total
N/A(5)
Phase 3(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05800301Phase 3Completed

Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision

Role: lead

NCT04877067Phase 3Completed

Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells With Electromagnetic Stimulation

Role: lead

NCT04252534Not ApplicableCompleted

Management of Retinitis Pigmentosa Via Electromagnetic Stimulation and Platelet Rich Plasma

Role: lead

NCT04242719Not ApplicableCompleted

Management of Deep Retinal Capillary Ischemia by Electromagnetic Stimulation and Platelet- Rich Plasma

Role: lead

NCT04238858Not ApplicableCompleted

Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa

Role: lead

NCT04234438Not ApplicableCompleted

Management of Cystoid Macular Edema Secondary to Retinitis Pigmentosa Via Subliminal Micropulse Yellow Laser

Role: lead

NCT04224831Not ApplicableCompleted

Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma

Role: lead

NCT04224207Phase 3Completed

Management of Retinitis Pigmentosa by Mesenchymal Stem Cells by Wharton's Jelly Derived Mesenchymal Stem Cells

Role: lead

All 8 trials loaded